| Property | Value |
|---|
|
?:abstract
|
-
The “Coronavirus Disease 2019 (COVID-19)” caused by “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)” has emerged in December 2019 and was announced as a pandemic by “World Health Organization” As of today, no specific therapeutics drugs are available for COVID-19 Thus patients have to rely on symptomatic adjuvant therapies Iron is critical in various physiological processes like DNA/RNA synthesis and generation of ATP In pathological condition, iron is vital for the host as well as the pathogen Lit-erature search revealed iron chelation therapy is one of the promising and emerging treatment modality for COVID-19 In pathological condition, iron is essential for the host as well as the pathogen like viruses which require intra-cellular iron for replication and propagation Sickle cell anaemia is hemolytic anaemia, where “Sickle haemoglobin (HbS)” is a structural variant of normal adult haemoglobin Haemoglobin composed of heam and globulin molecules An iron atom of heam helps in binding of oxygen molecules In sickle cell indi-viduals, haemoglobin concentration is reduced Thus viruses do not succeed in replication and proliferation due to deprived iron concentration;they may be less vulnerable for COVID-19 due to reduced iron load Another fact is that sickle cell individuals are immune to Malaria due to HbS Some reports say that the incidence of COVID-19 is less in Malaria population counties Thus it may be postulated that sickle cell individuals may also develop immunity to SARS-CoV-2, as evidenced by less incidence of COVID-19 in Malaria patients
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
International_Journal_of_Research_in_Pharmaceutical_Sciences
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Sickle cell individuals are less vulnerable for corona virus disease 2019-an enigma
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}